Katie Chow

BC Cancer Agency

Papers

1

Total Citations

42

H-Index

1

About

Dr. Katie Chow is a leading figure in the field of precision oncology and molecular diagnostics, with a primary focus on hereditary cancer syndromes. Her most impactful work centers on the development and clinical validation of next-generation sequencing assays for detecting germline mutations in the *BRCA1* and *BRCA2* genes. Her landmark 2013 study, which has garnered 42 citations, introduced a clinically validated second-generation sequencing assay that dramatically improved the accuracy, speed, and accessibility of hereditary breast and ovarian cancer risk assessment. This contribution has been instrumental in transitioning *BRCA* testing from costly, time-consuming methods to a streamlined, clinically actionable tool. By establishing rigorous validation protocols, Dr. Chow’s work has set a benchmark for diagnostic sequencing, directly enabling earlier interventions and personalized treatment strategies for at-risk patients. Her research bridges the gap between genomic technology and bedside care, making her a pivotal figure in the integration of molecular diagnostics into routine oncology practice.

Research Focus

Key Achievements

1
H-Index
1
Papers
42
Total Citations
42
Avg Citations/Paper
🏆 Most Cited Paper
A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations
42 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: BC Cancer Agency

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago